scholarly journals The Role of Antibody Polyspecificity and Lipid Reactivity in Binding of Broadly Neutralizing Anti-HIV-1 Envelope Human Monoclonal Antibodies 2F5 and 4E10 to Glycoprotein 41 Membrane Proximal Envelope Epitopes

2007 ◽  
Vol 178 (7) ◽  
pp. 4424-4435 ◽  
Author(s):  
S. Munir Alam ◽  
Mildred McAdams ◽  
David Boren ◽  
Michael Rak ◽  
Richard M. Scearce ◽  
...  
2013 ◽  
Vol 87 (24) ◽  
pp. 13936-13936
Author(s):  
Z. Zhu ◽  
H. R. Qin ◽  
W. Chen ◽  
Q. Zhao ◽  
X. Shen ◽  
...  

2020 ◽  
Vol 11 ◽  
Author(s):  
Wilfried Posch ◽  
Marta Bermejo-Jambrina ◽  
Cornelia Lass-Flörl ◽  
Doris Wilflingseder
Keyword(s):  
Anti Hiv ◽  

2018 ◽  
Vol 202 (3) ◽  
pp. 799-804 ◽  
Author(s):  
Melissa A. Gawron ◽  
Mark Duval ◽  
Claudia Carbone ◽  
Smita Jaiswal ◽  
Aaron Wallace ◽  
...  

2008 ◽  
Vol 117 (1) ◽  
pp. 35-44 ◽  
Author(s):  
Yuchang Li ◽  
Guanhua Li ◽  
Anna Ivanova ◽  
Sagiv Aaron ◽  
Malgorzata Simm

2004 ◽  
Vol 12 (02) ◽  
pp. 123-135 ◽  
Author(s):  
REBECCA V. CULSHAW

We present a review and comparison of several recent differential equations models of treatment of HIV-1 infection. We seek to clarify the role of the natural anti-HIV immune response and determine its effect upon optimal treatment schemes. In this paper, we consider systems in which treatment is expressed as a forcing function, as well as those in which we determine optimal treatment via control theoretic techniques. The primary goal of this study is to compare treatment schemes for systems in which a natural nonconstant immune response of the patient is considered explicitly with those that consider implicitly a constant non-specific immune response. We find that when the natural immune response can be boosted sufficiently, drug levels may not need to be as high as previously supposed. This implies that a treatment scenario in which intervals of drug treatment are alternated with some form of immune-boosting therapy may be highly beneficial in terms of reducing toxicity to the patient. Additionally, in developing countries where HIV infection is widespread and sufficient funds are not available to supply rigourous drug regimens, the implications of these models are profound, as they suggest methods of treating HIV at a minimal cost.


2017 ◽  
Vol 14 (1) ◽  
Author(s):  
Joseph T. Ortega ◽  
Alirica I. Suárez ◽  
Maria L. Serrano ◽  
Jani Baptista ◽  
Flor H. Pujol ◽  
...  
Keyword(s):  
Anti Hiv ◽  

2010 ◽  
Vol 207 (4) ◽  
pp. 763-776 ◽  
Author(s):  
M. Anthony Moody ◽  
Hua-Xin Liao ◽  
S. Munir Alam ◽  
Richard M. Scearce ◽  
M. Kelly Plonk ◽  
...  

Traditional antibody-mediated neutralization of HIV-1 infection is thought to result from the binding of antibodies to virions, thus preventing virus entry. However, antibodies that broadly neutralize HIV-1 are rare and are not induced by current vaccines. We report that four human anti-phospholipid monoclonal antibodies (mAbs) (PGN632, P1, IS4, and CL1) inhibit HIV-1 CCR5-tropic (R5) primary isolate infection of peripheral blood mononuclear cells (PBMCs) with 80% inhibitory concentrations of <0.02 to ∼10 µg/ml. Anti-phospholipid mAbs inhibited PBMC HIV-1 infection in vitro by mechanisms involving binding to monocytes and triggering the release of MIP-1α and MIP-1β. The release of these β-chemokines explains both the specificity for R5 HIV-1 and the activity of these mAbs in PBMC cultures containing both primary lymphocytes and monocytes.


Sign in / Sign up

Export Citation Format

Share Document